Skip to main content
Equibles

RHUMBLINE ADVISERS

Position in AKTS — Aktis Oncology, Inc.

CIK 1115418 BOSTON, MA
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 12, 2026
Position Value
$868,437
+$492,157 QoQ
Shares Held
26,945
+28.1% QoQ
Ownership
0.048%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#52
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 19% Shared 0% None 81%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. AKTS ranks #148 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 396,380 $196,893,837
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,794 $98,390,870
3 MRNA
Moderna, Inc.
 809,853 $56,714,005
4 ALNY
Alnylam Pharmaceuticals, Inc.
 165,579 $49,844,246
5 INCY
Incyte Corp
 428,533 $48,578,500
6 RVMD
Revolution Medicines, Inc.
 226,008 $42,326,778
7 ROIV
Roivant Sciences Ltd.
 1,178,789 $41,717,342
8 JAZZ
Jazz Pharmaceuticals plc
 163,018 $39,282,447

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $868,437 26,945
2026-03-31 $376,280 21,033